Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations

Lung Cancer

Volumn 70, Issue 2, 2010, Pages 200-204

  Trani, L ^a   Myerson, J ^b   Ashley, S ^b   Young, K ^b   Sheri, A ^b   Hubner, R ^b   Puglisi, M ^a   Popat, S ^b   O'Brien, M E R ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; Advanced NSCLC; Histology; Non adenocarcinoma; Non squamous; Outcome; Predictor; Prognosis; Squamous

Indexed keywords

GEMCITABINE; NAVELBINE; PLATINUM DERIVATIVE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 77957020074     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.02.003     Document Type: Article

References (29)

1. Novello S., Le Chevalier T. Chemotherapy for non-small cell lung cancer. Part 1. Early-stage disease. Oncology (Williston Park) 2003, 17:357-364.
2. Socinski M.A., Crowell R., Hensing T.E. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625. NSCLC Meta-Analysis Collaborative Group.
3. Langer C.J., Lilenbaum R., Sandler A.B., Morris D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:277S-289S.
4. D'Addario G., Felip E. ESMO guidelines working group non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl. 2):pii39-pii40.
5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for NSCLC. V.2.2008.
6. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM 2006, 355:2542-2550.
7. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) (FLEX); an open-label randomised phase III trial. Lancet 2009, 373(May (9674)):1525-1531.
8. Johnson D.H., Chang A.Y., Ettinger D.S., Kim K.M., Bonomi P. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of eastern cooperative oncology group (ECOG) trials from 1981-1992. Proc Am Soc Clin Oncol 1998, 17:461a.
9. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122:1037-1057.
10. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
11. Einhorn L. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. J Clin Oncol 2008, 26:3485-3486.
12. Hirsch F.R., Spreafico A., Novello S., Wood M.D., Simms L., Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481.
13. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
14. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003, 21:2237-2246.
15. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23:2556-2568.
16. Giaccone G., Gallegos Ruiz M., Le Chevalier T., Thatcher N., Smit E., Rodriguez J.A., et al. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. J Clin Oncol 2005, 23(16 suppl.):638s.
17. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. J Clin Oncol 2005, 23(16 suppl.):622s.
18. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
19. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previous treated non-small cell lung cancer. NEJM 2005, 353:123-132.
20. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 May 1, 22(9):1589-1597.
21. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14(March (3)):253-263.
22. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New guidelines to evaluate response to treatment in solid tumours (RECIST guidelines). J Natl Cancer Inst 2000, 92:205-216.
23. Tan E. Subset analysis of a phase III trial comparing two platinum-based doublets: i.v./oral vinorelbine (NVB) vs. docetaxel (DTX): impact of histology on response and survival in advanced non-small cell lung cancer (NSCLC). ECCO 15-34th ESMO Congress 2009, [abstract P-9078].
24. Grønberg B.H., Bremnes R.M., Fløtten O., Amundsen T., Brunsvig P.F., Hjelde H.H., et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(July (19)):3217-3224.
25. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009, 4(December (12)):1568-1571.
26. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292:470-484. 27.
27. Sederholm C., Hillerdal G., Lamberg K., Kölbeck K., Dufmats M., Westberg R., et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 2005, 23:8380-8388.
28. Charloux A., Hedelin G., Dietemann A. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer 1997, 17:123-134.
29. Sculier J.P., Chansky K., Crowley J.J., Van Meerbeeck J., Goldstraw P. The impact of additional prognostic factors on survival and their relationship with anatomical extent of disease expressed by the 6th edition of the TNM classification of Malignant Tumors and the proposals for 7th edition. J Thorac Oncol 2008 May, 3(5):457-466.